The three peripheral Crosser catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to cross chronic total occlusions (CTOs)to help restore blood flow to
This was the first of several regularly scheduled reviews by the Data Safety Monitoring Board (DSMB) that will occur over the duration of the trial. The purpose of
The option period will extend through the end of Phase II testing in the US. In consideration of investment, Medicis will receive preferred stock equivalent to nearly 10%
At the panel review, the members voted six to two in favor of recommending to the FDA that Kynapid be approved. An action further to the FDA review
The STAR (safety, tolerability and efficacy results of AVP-923 in pseudobulbar affect or PBA) trial will compare active treatment with Zenvia 30/10mg (dextromethorphan/quinidine or DM/Q) and Zenvia 20/10mg
Galapagos will receive total upfront fees of up to E3.5 million from GlaxoSmithKline (GSK), depending on the total number of programs within the collaboration. Galapagos could be eligible
The study is part of a larger clinical program examining the use of Interleukin-21 (IL-21) both as a single agent and in combination with approved cancer therapeutics. The
In addition, ENMD-981693 exhibited antiangiogenic activity in animal models by both inducing regression of formed blood vessels and preventing the formation of new blood vessels at well-tolerated doses.
This collaboration is expected to leverage GE Healthcare’s bioprocess solutions and design expertise and Novavax’s virus-like particle (VLP) and manufacturing platform. Novavax’s VLP-based H5N1 pandemic flu vaccine is
The license is expected to enhance Invitrogen’s growing portfolio of intellectual property surrounding click chemistry, originally developed by Nobel Laureate Barry Sharpless’s laboratory at The Scripps Research Institute
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.